Cargando…

The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers

BACKGROUND: A greater understanding of the everyday experiences of people with Parkinson’s disease (PD) and their carers may help improve clinical practice. OBJECTIVE: The Parkinson’s Real-world Impact assesSMent (PRISM) study evaluated medication use, health-related quality of life (HRQoL) and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tolosa, Eduardo, Ebersbach, Georg, Ferreira, Joaquim J., Rascol, Olivier, Antonini, Angelo, Foltynie, Thomas, Gibson, Rachel, Magalhaes, Diogo, Rocha, J. Francisco, Lees, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461669/ https://www.ncbi.nlm.nih.gov/pubmed/34024784 http://dx.doi.org/10.3233/JPD-212611

Ejemplares similares

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Sexual Dysfunctions in Parkinson’s Disease and Their Influence on Partnership—Data of the PRISM Study
por: Kinateder, Thomas, et al.
Publicado: (2022)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden
por: Modugno, Nicola, et al.
Publicado: (2020)

Patient-centred management of Parkinson's disease
por: Grimes, David, et al.
Publicado: (2020)

Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Challenges and Perspectives in the Management of Late-Stage Parkinson’s Disease
por: Fabbri, Margherita, et al.
Publicado: (2020)

Predictors of Burden in Carers of Patients with Impulse Control Behaviors in Parkinson's Disease
por: Johnson, Daniel, et al.
Publicado: (2023)

A Survey of People With Parkinson’s and Their Carers: The Management of Pain in Parkinson’s
por: Naisby, Jenni, et al.
Publicado: (2021)

Spanish version of the Parkinson’s Disease Questionnaire–Carer (PDQ-Carer)
por: Ferrer-Cascales, Rosario, et al.
Publicado: (2016)

Off-time Treatment Options for Parkinson’s Disease
por: Fabbri, Margherita, et al.
Publicado: (2023)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden [Corrigendum]
Publicado: (2021)

Correction to: Off-time Treatment Options for Parkinson’s Disease
por: Fabbri, Margherita, et al.
Publicado: (2023)

Using former carers’ expertise in peer support for carers of people with Parkinson’s Disease
por: Geerlings, Angelika D., et al.
Publicado: (2022)

Support Needs in Carers of People With Parkinson’s From Early to Later Stages: A Qualitative Study With 36 Carers in 11 European Countries
por: Merritt, Rowena K., et al.
Publicado: (2023)

Arm swing deviations in patients with Parkinson’s disease at different gait velocities
por: Mainka, Stefan, et al.
Publicado: (2023)

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Parkinson’s Disease Drug Development Since 1999: A Story of Repurposing and Relative Success
por: Boucherie, Deirdre M., et al.
Publicado: (2021)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Espresso Coffee for the Treatment of Somnolence in Parkinson’s Disease: Results of n-of-1 Trials
por: Ferreira, Joaquim J., et al.
Publicado: (2016)

Cognitive impairment in Parkinson's disease: impact on quality of life of carers
por: Lawson, RA, et al.
Publicado: (2016)

Validity and Reliability of the Korean Version of the Parkinson’s Disease Questionnaire–Carer
por: Lee, JuHee, et al.
Publicado: (2023)

Moving Forward with Prisms: Sensory-Motor Adaptation Improves Gait Initiation in Parkinson’s Disease
por: Bultitude, Janet H., et al.
Publicado: (2012)

LSVT LOUD and LSVT BIG: Behavioral Treatment Programs for Speech and Body Movement in Parkinson Disease
por: Fox, Cynthia, et al.
Publicado: (2012)

A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
por: Rascol, Olivier, et al.
Publicado: (2022)

Cognitive decline in Parkinson’s disease: the complex picture
por: Biundo, Roberta, et al.
Publicado: (2016)

The Role of Parkinson Nurses for Personalizing Care in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: van Munster, Marlena, et al.
Publicado: (2022)

Moving towards Integrated and Personalized Care in Parkinson’s Disease: A Framework Proposal for Training Parkinson Nurses
por: van Munster, Marlena, et al.
Publicado: (2021)

Factors Influencing Habitual Physical Activity in Parkinson’s Disease: Considering the Psychosocial State and Wellbeing of People with Parkinson’s and Their Carers
por: Mc Ardle, Ríona, et al.
Publicado: (2022)

Therapies to Slow, Stop, or Reverse Parkinson’s Disease
por: Foltynie, Tom, et al.
Publicado: (2018)

Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions
por: Ferreira, J. J., et al.
Publicado: (2019)

Screening for VPS35 mutations in Parkinson's disease
por: Sheerin, Una-Marie, et al.
Publicado: (2012)

Are Patient and Carer Experiences Mirrored in the Practice Reviews of Self-management Support (Prisms) Provider Taxonomy?
por: Sheridan, Nicolette, et al.
Publicado: (2017)

Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series
por: Foltynie, T., et al.
Publicado: (2013)

Current and novel infusion therapies for patients with Parkinson's disease
por: Antonini, Angelo, et al.
Publicado: (2023)

The Power of Musification: Sensor‐Based Music Feedback Improves Arm Swing in Parkinson's Disease
por: Mainka, Stefan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4tbab2qnal5k18aj07q9sa3bm9